Condition 1: Hodgkin lymphoma. Condition 2: Follicular lymphoma. Condition 3: Non-follicular lymphoma. Hodgkin lymphoma Follicular lymphoma Non-follicular lymphoma
Conditions
Interventions
Intervention group: All patients are included in the only intervention arm of the study. Patients in the intervention arm will receive a dose of 10 million/kg expanded NK cells on the day after the co
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18 years or older adequate organ function at the time of infusion After the failure of at least 2 prior lines of therapy Histologically confirmed malignant lymphoma Adequate performance score: KPS >70 or ECOG 0-2
Exclusion criteria
Exclusion criteria: CNS lymphoma HIV patients Patients with a history of autoimmune disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Patients With Grades 3-5 of Natural Killer cell infusion-related Adverse Events. Timepoint: Daily during the first seven days after the injection and then weekly until 28 days after the injection. Method of measurement: History, Physical exam, and lab test.;Number of Patients With Grades III-IV Acute Graft versus Host Disease. Timepoint: Daily during the first seven days after the injection and then weekly until 3 months after intervention. Method of measurement: History, Physical exam, and lab test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohamad Ahmadvand
Tehran University of Medical Sciences
Outcome results
None listed